President of Sanofi France expects COVID-19 vaccine to be priced below ten Euros

pharmafile | September 7, 2020 | News story | Sales and Marketing COVID-19, GSK, Sanofi 

The President of Sanofi France expects the coronavirus vaccine it is developing with GlaxoSmithKline to be priced under 10 Euros. 

The President, Olivier Bogillot, told France Inter radio: “The price is not totally set. We are assessing production costs for the coming months. We will be below 10 euros. The price gap for us can be that we use all our internal resources, our own researchers, our own research centres. AstraZeneca outsources part of its production.

“We anticipate being able to determine a final price at the time of our Phase 3 trials, when we know more about dosing. At this stage, any figure is imprecise. Less than 10 euros is only one of the hypotheses we are working on.”

At the start of the month the two companies began clinical trials of their vaccine that are set to involve 440 adults across 11 sites in the US. It is a randomised, double-blind, placebo-controlled trial designed to evaluate the safety and tolerability of the vaccine. 

Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, commented on the study: “The initiation of our clinical study is an important step and brings us closer to a potential vaccine which could help defeat COVID-19. Our dedicated teams and partners continue to work around the clock as we aim to deliver the first results in early December. Positive data will enable a prompt start of the pivotal Phase 3 trial by the end of this year.”

The two companies also agreed a deal with the US to provide them with 100 million doses of this vaccine as part of Operation Warp Speed. Sanofi is also working on an mRNA vaccine with Translate Bio. 

Conor Kavanagh

Related Content

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has …

Pharmanovia acquires CNS portfolio from Sanofi

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a …

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …

Latest content